Abstract
Despite the discovery that the human immunodeficiency virus 1 (HIV-1) is the pathogen of acquired immunodeficiency syndrome (AIDS) in 1983, there is still no effective anti-HIV-1 vaccine. The major obstacle to the development of HIV-1 vaccine is the extreme diversity of viral genome sequences. Nonetheless, a number of broadly neutralizing antibodies (bNAbs) against HIV-1 have been made and identified in this area. Novel strategies based on using these bNAbs as an efficacious preventive and/or therapeutic intervention have been applied in clinical. In this review, we summarize the recent development of bNAbs and its application in HIV-1 acquisition prevention as well as discuss the innovative approaches being used to try to convey protection within individuals at risk and being treated for HIV-1 infection.
Keywords:
AIDS; HIV-1; bNAb; prevention; therapy.
Copyright © 2021 Ding, Patel, Ma, Mann, Wu and Gao.
Publication types
-
Research Support, Non-U.S. Gov't
-
Systematic Review
MeSH terms
-
AIDS Vaccines / genetics
-
AIDS Vaccines / immunology
-
Animals
-
Antibody Specificity
-
Broadly Neutralizing Antibodies / classification
-
Broadly Neutralizing Antibodies / immunology
-
Broadly Neutralizing Antibodies / therapeutic use*
-
Gene Transfer Techniques
-
Genes, env
-
Genetic Therapy
-
Genetic Variation
-
HIV Antibodies / classification
-
HIV Antibodies / immunology
-
HIV Antibodies / therapeutic use*
-
HIV Infections / immunology
-
HIV Infections / prevention & control*
-
HIV Infections / therapy*
-
HIV-1 / genetics
-
HIV-1 / immunology*
-
Humans
-
Immunity, Humoral
-
Immunization, Passive
-
Models, Immunological
-
Vaccine Development
-
env Gene Products, Human Immunodeficiency Virus / genetics
-
env Gene Products, Human Immunodeficiency Virus / immunology
Substances
-
AIDS Vaccines
-
Broadly Neutralizing Antibodies
-
HIV Antibodies
-
env Gene Products, Human Immunodeficiency Virus